While OS is still the king of the oncology endpoints, experts note it may soon be phased out due to the introduction of ...

Johnson & Johnson announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted ...

In top-line results, the phase III trial demonstrated a “highly clinically meaningful reduction” in 24-hour systolic BP.

Enanta Pharmaceuticals remains a Buy as zelicapavir shows promise in RSV trials; strong financials support growth. Read why ...

Discover the top 10 EDR tools for CIOs in 2025 that enhance endpoint protection, accelerate threat investigations, and reduce ...

To get ahead of disruption and risk, forward-thinking organizations are turning to unified endpoint management (UEM) ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has become the first drug ...

Get ready to explore the thrilling rumors surrounding Wrath of the Lich King Classic! With discussions heating up around the intriguing "wowdev3" endpoint, the World of Warcraft community is buzzing ...

A phase 3 trial evaluating benralizumab for the treatment of COPD did not meet its primary endpoint, according to AstraZeneca.

Enata Pharmaceuticals said it didn't meet its primary endpoint in a Phase 2b study of zelicapavir, its proposed treatment for Respiratory Syncytial Virus, or RSV, in high-risk adults.

In a large PPMS population that included older patients and people with more advanced disease, ocrelizumab led to a 30% risk ...

Protecting critical systems calls for a disciplined approach that mirrors battlefield tactics in its emphasis on awareness, ...